Search Results - "Stilgenbauer, S."

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial by Hallek, M, Prof, Fischer, K, MD, Fingerle-Rowson, G, MD, Fink, AM, MD, Busch, R, Mayer, J, Prof, Hensel, M, Prof, Hopfinger, G, MD, Hess, G, MD, von Grünhagen, U, MD, Bergmann, M, MD, Catalano, J, MD, Zinzani, PL, Prof, Caligaris-Cappio, F, Prof, Seymour, JF, Prof, Berrebi, A, Prof, Jäger, U, Prof, Cazin, B, MD, Trneny, M, MD, Westermann, A, Wendtner, CM, Prof, Eichhorst, BF, MD, Staib, P, MD, Bühler, A, MD, Winkler, D, MD, Zenz, T, MD, Böttcher, S, MD, Ritgen, M, MD, Mendila, M, MD, Kneba, M, Prof, Döhner, H, Prof, Stilgenbauer, S, Prof

“…Summary Background On the basis of promising results that were reported in several phase 2 trials, we investigated whether the addition of the monoclonal…”
Get full text

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation by Malcikova, J., Tausch, E., Rossi, D., Sutton, L. A., Soussi, T., Zenz, T., Kater, A. P., Niemann, C. U., Gonzalez, D., Davi, F., Gonzalez Diaz, M., Moreno, C., Gaidano, G., Stamatopoulos, K., Rosenquist, R., Stilgenbauer, S., Ghia, P., Pospisilova, S.

“…In chronic lymphocytic leukemia (CLL), TP53 gene defects, due to deletion of the 17p13 locus and/or mutation(s) within the TP53 gene, are associated with…”
Get full text

Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL by Schrader, A., Crispatzu, G., Oberbeck, S., Mayer, P., Pützer, S., von Jan, J., Vasyutina, E., Warner, K., Weit, N., Pflug, N., Braun, T., Andersson, E. I., Yadav, B., Riabinska, A., Maurer, B., Ventura Ferreira, M. S., Beier, F., Altmüller, J., Lanasa, M., Herling, C. D., Haferlach, T., Stilgenbauer, S., Hopfinger, G., Peifer, M., Brümmendorf, T. H., Nürnberg, P., Elenitoba-Johnson, K. S. J., Zha, S., Hallek, M., Moriggl, R., Reinhardt, H. C., Stern, M.-H., Mustjoki, S., Newrzela, S., Frommolt, P., Herling, M.

“…T-cell prolymphocytic leukemia (T-PLL) is a rare and poor-prognostic mature T-cell malignancy. Here we integrated large-scale profiling data of alterations in…”
Get full text

Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials by Al-Sawaf, O., Robrecht, S., Bahlo, J., Fink, A. M., Cramer, P., v Tresckow, J., Lange, E., Kiehl, M., Dreyling, M., Ritgen, M., Dürig, J., Tausch, E., Schneider, C., Stilgenbauer, S., Wendtner, C. M., Fischer, K., Goede, Hallek, M., Eichhorst, B.

“…Richter transformation (RT) is defined as development of aggressive lymphoma in patients (pts) with CLL. The incidence rates of RT among pts with CLL range…”
Get full text

Recurrent mutations refine prognosis in chronic lymphocytic leukemia by Baliakas, P, Hadzidimitriou, A, Sutton, L-A, Rossi, D, Minga, E, Villamor, N, Larrayoz, M, Kminkova, J, Agathangelidis, A, Davis, Z, Tausch, E, Stalika, E, Kantorova, B, Mansouri, L, Scarfò, L, Cortese, D, Navrkalova, V, Rose-Zerilli, M J J, Smedby, K E, Juliusson, G, Anagnostopoulos, A, Makris, A M, Navarro, A, Delgado, J, Oscier, D, Belessi, C, Stilgenbauer, S, Ghia, P, Pospisilova, S, Gaidano, G, Campo, E, Strefford, J C, Stamatopoulos, K, Rosenquist, R

“…Through the European Research Initiative on chronic lymphocytic leukemia (CLL) (ERIC), we screened 3490 patients with CLL for mutations within the NOTCH1 ( n…”
Get full text

Treatment of Older Patients with Mantle-Cell Lymphoma by Kluin-Nelemans, H.C, Hoster, E, Hermine, O, Walewski, J, Trneny, M, Geisler, C.H, Stilgenbauer, S, Thieblemont, C, Vehling-Kaiser, U, Doorduijn, J.K, Coiffier, B, Forstpointner, R, Tilly, H, Kanz, L, Feugier, P, Szymczyk, M, Hallek, M, Kremers, S, Lepeu, G, Sanhes, L, Zijlstra, J.M, Bouabdallah, R, Lugtenburg, P.J, Macro, M, Pfreundschuh, M, Procházka, V, Di Raimondo, F, Ribrag, V, Uppenkamp, M, André, M, Klapper, W, Hiddemann, W, Unterhalt, M, Dreyling, M.H

“…This international prospective study showed that maintenance therapy with rituximab was more effective than interferon alfa in prolonging the duration of…”
Get full text

IN3 From biology to therapy in chronic lymphocytic leukaemia by Stilgenbauer, S

Get full text

ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia by Pospisilova, S, Gonzalez, D, Malcikova, J, Trbusek, M, Rossi, D, Kater, A P, Cymbalista, F, Eichhorst, B, Hallek, M, Döhner, H, Hillmen, P, van Oers, M, Gribben, J, Ghia, P, Montserrat, E, Stilgenbauer, S, Zenz, T

“…Recent evidence suggests that – in addition to 17p deletion – TP53 mutation is an independent prognostic factor in chronic lymphocytic leukemia (CLL). Data…”
Get full text

ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL) by Ghielmini, M., Vitolo, U., Kimby, E., Montoto, S., Walewski, J., Pfreundschuh, M., Federico, M., Hoskin, P., McNamara, C., Caligaris-Cappio, F., Stilgenbauer, S., Marcus, R., Trneny, M., Dreger, P., Montserrat, E., Dreyling, M., Agostinelli, Claudio, Arcaini, Luca, Caligaris-Cappio, Federico, Campo, Elias, Coiffier, Bertrand, Corradini, Paolo, D'Amore, Francesco, Dreger, Peter, Dreyling, Martin, Federico, Massimo, Gallamini, Andrea, Gaulard, Philippe, Geisler, Christian H., Ghielmini, Michele, Gisselbrecht, Christian, da Silva, Maria Gomes, Gribben, John, Hermine, Olivier, Hoskin, Peter, Iannitto, Emilio, Kim, Won Seog, Kimby, Eva, Kluin-Nelemans, Hanneke C., Koch, Peter, Ladetto, Marco, Le Gouill, Steven, Lopez-Guillermo, Armando, Marcus, Robert, McNamara, Christopher, Montalban, Carlos, Montoto, Silvia, Montserrat, Emili, Pfreundschuh, Michael, Raderer, Markus, Rodriguez, José, Salles, Gilles, Bernard, Claude, Schmitz, Norbert, Shpilberg, Ofer, Stilgenbauer, Stephan, Thieblemont, Catherine, Tilly, Hervé, Tournilhac, Olivier, Trümper, Lorenz, Vitolo, Umberto, Walewski, Jan, Wotherspoon, Andrew, Zucca, Emanuele

“…To complete the existing treatment guidelines for all tumor types, ESMO organizes consensus conferences to better clarify open issues in each disease. In this…”
Get full text

Defective DROSHA processing contributes to downregulation of MiR-15/-16 in chronic lymphocytic leukemia by Allegra, D, Bilan, V, Garding, A, Döhner, H, Stilgenbauer, S, Kuchenbauer, F, Mertens, D

“…The MIR-15A/-16-1 tumor suppressor microRNAs (miRNAs) are deleted in leukemic cells from more than 50% of patients with chronic lymphocytic leukemia (CLL). As…”
Get full text

Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials by Goede, Valentin, Cramer, Paula, Busch, Raymonde, Bergmann, Manuela, Stauch, Martina, Hopfinger, Georg, Stilgenbauer, Stephan, Döhner, Hartmut, Westermann, Anne, Wendtner, Clemens M, Eichhorst, Barbara, Hallek, Michael

“…This study investigated the impact of comorbidity in 555 patients with chronic lymphocytic leukemia enrolled in two trials of the German Chronic Lymphocytic…”
Get full text

Genetics of chronic lymphocytic leukemia: genomic aberrations and VH gene mutation status in pathogenesis and clinical course by STILGENBAUER, S, BULLINGER, L, LICHTER, P, DÖHNER, H

“…The genetic characterization of chronic lymphocytic leukemia (CLL) has made significant progress over the past few years. While conventional cytogenetic…”
Get full text

Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia by Parker, H, Rose-Zerilli, M J J, Larrayoz, M, Clifford, R, Edelmann, J, Blakemore, S, Gibson, J, Wang, J, Ljungström, V, Wojdacz, T K, Chaplin, T, Roghanian, A, Davis, Z, Parker, A, Tausch, E, Ntoufa, S, Ramos, S, Robbe, P, Alsolami, R, Steele, A J, Packham, G, Rodríguez-Vicente, A E, Brown, L, McNicholl, F, Forconi, F, Pettitt, A, Hillmen, P, Dyer, M, Cragg, M S, Chelala, C, Oakes, C C, Rosenquist, R, Stamatopoulos, K, Stilgenbauer, S, Knight, S, Schuh, A, Oscier, D G, Strefford, J C

“…Histone methyltransferases (HMTs) are important epigenetic regulators of gene transcription and are disrupted at the genomic level in a spectrum of human…”
Get full text

Effect of first-line treatment on second primary malignancies and Richter’s transformation in patients with CLL by Maurer, C, Langerbeins, P, Bahlo, J, Cramer, P, Fink, A M, Pflug, N, Engelke, A, von Tresckow, J, Kovacs, G, Stilgenbauer, S, Wendtner, C-M, Müller, L, Ritgen, M, Seiler, T, Fischer, K, Hallek, M, Eichhorst, B

“…This study aimed to assess the frequency of and the contributing factors for second primary malignancies (SPMs) and Richter’s transformations (RTs) following…”
Get full text

ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia by Ghia, P, Stamatopoulos, K, Belessi, C, Moreno, C, Stilgenbauer, S, Stevenson, F, Davi, F, Rosenquist, R

Get full text

Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group by Hoechstetter, M A, Busch, R, Eichhorst, B, Bühler, A, Winkler, D, Eckart, M J, Vehling-Kaiser, U, Schimke, H, Jäger, U, Hurtz, H J, Hopfinger, G, Hartmann, F, Fuss, H, Abenhardt, W, Blau, I, Freier, W, Müller, L, Goebeler, M, Wendtner, C M, Bahlo, J, Fischer, K, Bentz, M, Emmerich, B, Döhner, H, Hallek, M, Stilgenbauer, S

Get full text

Noncanonical effector functions of the T-memory–like T-PLL cell are shaped by cooperative TCL1A and TCR signaling by Oberbeck, S., Schrader, A., Warner, K., Jungherz, D., Crispatzu, G., von Jan, J., Chmielewski, M., Ianevski, A., Diebner, H.H., Mayer, P., Kondo Ados, A., Wahnschaffe, L., Braun, T., Müller, T.A., Wagle, P., Bouska, A., Neumann, T., Pützer, S., Varghese, L., Pflug, N., Thelen, M., Makalowski, J., Riet, N., Göx, H.J.M., Rappl, G., Altmüller, J., Kotrová, M., Persigehl, T., Hopfinger, G., Hansmann, M.L., Schlößer, H., Stilgenbauer, S., Dürig, J., Mougiakakos, D., von Bergwelt-Baildon, M., Roeder, I., Hartmann, S., Hallek, M., Moriggl, R., Brüggemann, M., Aittokallio, T., Iqbal, J., Newrzela, S., Abken, H., Herling, M.

“…T-cell prolymphocytic leukemia (T-PLL) is a poor-prognostic neoplasm. Differentiation stage and immune-effector functions of the underlying tumor cell are…”
Get full text

Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton by Knudsen, P B, Hanna, B, Ohl, S, Sellner, L, Zenz, T, Döhner, H, Stilgenbauer, S, Larsen, T O, Lichter, P, Seiffert, M

“…Chronic lymphocytic leukemia (CLL) is an incurable malignancy of mature B cells. One of the major challenges in treatment of CLL is the achievement of a…”
Get full text

Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis by Böttcher, S, Stilgenbauer, S, Busch, R, Brüggemann, M, Raff, T, Pott, C, Fischer, K, Fingerle-Rowson, G, Döhner, H, Hallek, M, Kneba, M, Ritgen, M

“…Rituximab-containing regimens are becoming a therapeutic standard in chronic lymphocytic leukemia (CLL), so that a validation of flow cytometric minimal…”
Get full text

Lamin B1 regulates somatic mutations and progression of B-cell malignancies by Klymenko, T, Bloehdorn, J, Bahlo, J, Robrecht, S, Akylzhanova, G, Cox, K, Estenfelder, S, Wang, J, Edelmann, J, Strefford, J C, Wojdacz, T K, Fischer, K, Hallek, M, Stilgenbauer, S, Cragg, M, Gribben, J, Braun, A

“…Somatic hypermutation (SHM) is a pivotal process in adaptive immunity that occurs in the germinal centre and allows B cells to change their primary DNA…”
Get full text